Hypovitaminosis D and secondary hyperparathyroidism are frequent among HIV-infected patients. As there are no data about the best supplementation therapy both in treatment and in maintenance, we conducted an observational study of 300 HIV-infected patients for whom vitamin D and parathormone (PTH) had been measured in order to validate a protocol of vitamin D supplementation in patients with HIV-infection. Patients with vitamin D deficiency (defined as 25(OH)D < 10 ng/mL), insufficiency (defined as 25(OH)D < 20 ng/mL), or hyperparathyroidism (PTH > 65 pg/mL) were supplemented with cholecalciferol 16,000 IU (0.266 mg) weekly (if deficiency) or fortnightly (if insufficiency or high PTH levels). Rates of normalization of 25(OH)D (levels above 20 ng/mL) and PTH levels (< 65 pg/mL) were analyzed. Multivariate analysis of factors related to normalization was carried out. With a median follow-up of 2 years, 82.1% of patients with deficiency and 83.9% of cases with insufficiency reached levels above 20 ng/mL. However, only 67.2% of individuals with hyperparathyroidism at baseline reached target levels (<65 pg/mL). Independent factors for not achieving PTH objective were tenofovir (TDF) and protease inhibitors use. In HIV-infected patients with hypovitaminosis, the protocol of cholecalciferol supplementation normalized vitamin D levels regardless of antiretroviral regimen in a high proportion of patients but it was less effective to correct hyperparathyroidism.

1. Introduction

In recent years, a growing number of studies have reported high prevalence rates of vitamin D deficiency among HIV-infected patients [1]. The prevalence of hypovitaminosis goes from 42 to 95% in different studies [2–4]. In a previous study conducted in our hospital hypovitaminosis was reported in as many as 71.2% of HIV-infected patients (39.6% of them were vitamin D deficient as defined by levels below 10 ng/mL) [5].

The relevance of the high prevalence of hypovitaminosis D among HIV patients is that vitamin D is not only a well-established factor for bone disease [6–11], but also associated with nonskeletal conditions, including cardiovascular, immune regulation, cancer, and neurocognitive disorders [12–14]. Moreover, some studies suggest that severe vitamin D deficiency is associated with HIV progression, mortality, and AIDS events [2].

Risk factors for hypovitaminosis D are female sex, dark skin pigmentation, low dietary intake, seasonality, insufficient sun exposure, and high body mass index [15–19]. Recently we also identified as predictors of vitamin D deficiency in HIV-infected patients the existence of psychiatric comorbidity while lipoatrophy was a protective factor [5]. In addition to all classic risk factors, these subjects are also exposed to HIV-related factors associated with vitamin D deficiency such as immune activation, chronic inflammation,
and viral and antiretroviral treatment with potential interactions on the vitamin D metabolism [20–26].

The systematic screening for vitamin D deficiency is controversial. The most recent EACS guidelines [27] suggest screening for hypovitaminosis D for every HIV-positive subject having a bone disease (low bone mineral density, previous fractures, or high risk for fractures) or other known factors for vitamin D deficiency. Vitamin D repletion is recommended when 25(OH)D levels are below 10 ng/mL. Furthermore it may be indicated in presence of vitamin D values between 10 and 30 ng/mL if associated with bone disease or secondary hyperparathyroidism. Elevated levels of PTH as a consequence of chronic vitamin D deficiency have been linked to bone loss [28]. Accordingly, EACS guidelines recommend vitamin D supplementation to reach levels above 20 ng/mL and normalizing serum PTH levels [27].

Arguments against the widespread screening for vitamin D deficiency in HIV-infected patients include the unclear benefit of vitamin D replacement for nonmusculoskeletal outcomes, the cost of laboratory testing and treatment, and the potential toxicities of some supplementation approaches [29]. Furthermore, the optimal repletion and maintenance dosing regimens remain to be established as well as the impact of vitamin D supplementation in preventing comorbidities [1]. Another study proposed that a dose of 16.000 IU calcidiol monthly during 9 months [30] was efficacy in decreasing the prevalence of hypovitaminosis D and the rates of associated hyperparathyroidism.

Therefore, accepting the evidence that adequate vitamin D levels are beneficial for HIV patients we implemented a protocol for vitamin D supplementation and analyzed the factors influencing the achievement of these target levels in a clinical population where a protocol for vitamin D supplementation has been implemented. Moreover, we also analyzed the relationship between vitamin D and PTH levels.

2. Materials and Methods

2.1. Patients and Study Design. An observational study was conducted at the Department of Infectious Diseases at Hospital del Mar (Barcelona, Spain), analyzing 300 HIV-infected out-patients who were naïve or on stable HAART (highly active antiretroviral therapy) for whom vitamin D levels had been measured (fasting status). Patients were followed up in our department and visited between June 2010 and October 2013. The study was approved by the hospital ethical committee and all subjects provided written informed consent. All patients’ data were anonymized for data management and statistical analysis. As an observational study, there was no control arm for comparison and hence no randomization.

2.2. Quantification of Laboratory Values. Vitamin D (competitive electrochemiluminescence protein binding assay, Cobas e602, Roche Diagnostics, Germany) status was categorized as insufficient when <20 ng/mL and deficient when <10 ng/mL and hyperparathyroidism as PTH levels (solid-phase, two-site chemiluminescence enzyme-labeled immuno-assay; IMMULITE 2000, Siemens; Los Angeles, CA, USA) >65 pg/mL. Secondary laboratory variables included serum levels of calcium (8.5–10.5 mg/dL), phosphate (2.5–4.8 mg/dL), alkaline phosphatase (40–129 IU/L), CD4 and CD8 lymphocytes counts, and HIV viral load (COBAS, AmpliPrep/TaqMan HIV-1 test, Roche Diagnostics).

The following demographic and clinical data were assessed: gender, age, race, risk factors for HIV-infection, HAART, and hepatitis C and B coinfection. For the analysis were excluded patients with renal insufficiency (defined as glomerular rate filtration <60 mL/min, estimated using Modification of Diet in Renal Disease (MDRD) equation), hepatic insufficiency (defined as Child Pugh stage C), patients under chemotherapy, and those already receiving vitamin D, bisphosphonates, and calcium supplements (and the other classical exclusion criteria).

Subjects were supplemented with 16.000 IU or 0.266 mg of vitamin D3 (cholecalciferol, Hidroferol®, FAES FARMA) weekly, fortnightly, or monthly according to vitamin D baseline and PTH concentrations and according to the supplementation protocol designed by the Department of Infectious Diseases at Hospital del Mar (Figure 1). Those patients with vitamin D below 10 ng/mL were supplemented with 16.000 IU of cholecalciferol weekly. Patients with vitamin D above 10 ng/mL were replaced according to PTH values, though for those with PTH > 70 ng/mL 1 dose fortnightly was used and those with PTH < 65 ng/mL did not receive supplements. All subjects were reevaluated after 4–6 months and at every outpatient visit thereafter up to two years of follow-up. If vitamin D levels reached levels between 30 ng/mL and 100 ng/mL, the dose was modified to 16.000 IU fortnightly. When serum vitamin D reached levels above 100 ng/mL the dosage was modified to 16.000 IU every month. During the follow-up all patients were reevaluated 3 times. Subjects with normal vitamin D levels were not supplemented. Vitamin D toxicity was defined as concentrations above 150 ng/mL [31].

2.3. Statistical Analysis. Univariate analyses were performed with chi-square test and ORs and its 95% confidence interval was estimated by logistic regression.

Data of 300 participants from the 3 follow-up moments were pooled resulting in 798 registers. With the data arranged in this manner a Linear Mixed Model was performed to analyse the relationship between PTH and vitamin D, adjusted by TDF. In this model the individual (the identifier) was included as a random effect.

To analyse the factors associated to achieve the objective of 25(OH)D level above 20 ng/mL and PTH level below 65 pg/mL a chi-square analysis was done for the univariate analysis and a logistic regression model for the multivariate analysis; both analyses were done in patients with baseline 25(OH)D < 20 ng/mL and baseline 25(OH)D < 10 ng/mL.

Statistical analysis was performed with R Statistical Package (R Foundation for Statistical Computing, Vienna, Austria; Version 2.15.1).

3. Results

3.1. Study Population. The characteristics of the 300 patients included in the study are presented in Table 1. The median
age of participants was 46 years (range 41–52), 219 (73%) were males, and 253 (84.3%) were caucasians. Predominant risk groups for HIV-transmission were IDU (intravenous drug users) (36.7%) and MSM (men having sex with men) (35.3%). At the time of sampling 283 patients (95.3%) were on cART; from those 173 (57%) were exposed to TDF, 130 (43.3%) to nonnucleoside reverse transcriptase inhibitors (NNRTI), and 173 (55%) to ritonavir-boosted protease inhibitor regimen (PI). The proportions of vitamin D deficiency and insufficiency were 28% and 62%, respectively, and 45.7% of the patients had secondary hyperparathyroidism.

The protocol described in Figure 1 was intended to be applied in the 300 HIV-infected patients.

3.2. Changes in Vitamin D and PTH. At baseline, 84 patients were vitamin D deficient and 186 insufficient. All patients, both deficient and insufficient, were offered supplementation but all those who declined this option were not supplemented. A total amount of 22 patients of those with vitamin D deficiency and 58 of those with insufficiency declined supplementation.

62 patients with vitamin D deficiency (73.8%) were supplemented (Table 2). After completing 24 months, 2 (3.2%) participants receiving vitamin D had a trough serum 25(OH)D concentration <20 ng/mL compared to 13 (59.1%) of those not supplemented (p < 0.0001). Vitamin D objective was influenced by neither TDF exposure (p: 0.65) nor non-nucleoside exposure (p: 0.23). A high proportion of patients on PI therapy achieved 25(OH)D concentration >20 ng/mL (89.4% versus 73%; p: 0.08); however, the difference did not reach statistical significance. At the multivariate analysis, the only significant factor associated with achieving the objective of 25(OH)D concentration >20 ng/mL was cholecalciferol supplementation (p < 0.0001).

Table 3 shows the factors associated with PTH objective (PTH < 65 pg/mL) in patients with vitamin D deficiency. Vitamin D supplements had no effect over PTH objective, but
Table 2: Patients with vitamin D < 10 ng/mL at baseline. Objective vitamin D > 20 ng/mL. Univariate and multivariate analysis.

|                      | Univariate analysis | Multivariate analysis |
|----------------------|---------------------|-----------------------|
|                      | Objective yes: 69 (82.1%) | Objective no: 15 (17.9%) | p | OR (95% CI) | p |
| VitD supplements      |                     |                       |   |             |   |
| Yes                  | 60 (96.8)           | 2 (3.2)               | 0.0001 | 66.76 (10.06–442.85) | 0.0001 |
| No                   | 9 (40.9)            | 13 (59.1)             |       |             |   |
| TDF exposure         |                     |                       |   |             |   |
| Yes                  | 32 (84.2)           | 6 (15.8)              | 0.65 |             |   |
| No                   | 37 (80.4)           | 9 (19.6)              |       |             |   |
| NNRTI exposure       |                     |                       |   |             |   |
| Yes                  | 26 (76.5)           | 8 (23.5)              | 0.26 |             |   |
| No                   | 43 (86)             | 7 (14)                |       |             |   |
| PIs exposure         |                     |                       |   |             |   |
| Yes                  | 42 (89.4)           | 5 (10.6)              | 0.08 |             |   |
| No                   | 27 (73)             | 10 (27)               |       |             |   |

Table 3: Linear Mixed Model, PTH dependent variable.

| Variable | Slope | 95% CI | Correlation | p value |
|----------|-------|--------|-------------|---------|
| VitD     | −0.213 | −0.291 | −0.134 | <0.001 |
| TDF      | 10.643 | 4.861 | 16.425 | <0.001 |

at the logistic regression tenofovir exposure was a risk factor associated with not achieving PTH objective (OR: 3.77 (1.36–10.43)).

The results were similar in those subjects with vitamin D insufficiency. The proportion of participants with vitamin D <20 ng/mL was 62% (186 patients) of whom 128 subjects were supplemented with cholecalciferol. More patients in the supplemented regimen achieved vitamin D concentration >20 ng/mL after treatment than those not supplemented (95.5% compared with 53.8%, resp.; p = 0.0001). Table 4 summarizes the factors associated with reaching both objectives, vitamin D and PTH. As in the patients with vitamin D deficiency, PI based therapies and those with TDF exposure were associated with a higher risk of not achieving PTH levels under 65 pg/mL.

Although cholecalciferol supplementation did not seem to correct the secondary hyperparathyroidism in the qualitative analysis it had an effect over PTH concentration so for each increasing unit of vitamin D, PTH decreased 0.213 pg/mL (p < 0.001). Moreover, PTH values were significantly higher, 10.643 pg/mL, in those patients exposed to TDF (p < 0.001) (Table 5).

No changes on HAART due to vitamin D for PTH levels were made. Those HAART switches during supplementation were made for either virologic failure or adverse events related to antiretroviral therapy.

There were no differences between patients supplemented and those not with respect to the frequencies of possible adverse events including infectious diseases, fractures, cancer, and cardiovascular diseases, so we considered there were no events attributable to vitamin D replacement. During the course of the study no patient in replacement group presented toxicities (no hypercalcemia). The mean viral load, CD4 number and CD4%, calcium, phosphate, and alkaline phosphatase measurements did not differ between baseline and the end of the study.

4. Discussion

Considering that hypovitaminosis is associated with unfavorable outcomes of some chronic infections such as HIV [32] and the increasing evidence of its role in innate and cell mediated immunity [33] we proposed a practical scheme for vitamin D supplementation. When designing this protocol we focused on several problems. First of all, the recent development of the once-daily single tablet regimen has optimized HAART regimens and improved long term adherence, as well as quality of life [34]. But HAART has also increased life expectancy and therefore age-related morbidities as well as the need for concomitant medication. In a recent study, suboptimal adherence was associated with greater pill burden and higher maximum number of doses per day [35]. The aim of the proposed scheme was the avoidance of adherence problems; thus we designed a protocol in which we could give the least possible number of doses: maximum 1 per week and at least 1 monthly. On the other hand recommendations on screening and vitamin D supplementation remain sparse and controversial and the target level of vitamin D to be reached after replacement is not yet known. Some investigators consider that a minimum serum concentration of 30 ng/mL is necessary, whereas others suggest that the calcitropic functions of vitamin D are enhanced with higher concentrations of serum 25(OH)D within the current reference range [36–39].

The results of this study demonstrate that supplementation of HIV-infected individuals with vitamin D is well
Table 4: Patients with vitamin D < 10 ng/mL at baseline. Objective PTH < 65 pg/mL.

|                          | Objective yes 56 (66.7) | Univariate analysis | Multivariate analysis |
|--------------------------|-------------------------|---------------------|-----------------------|
|                          |                         | OR (95% CI)         | p                     |
| **VitD supplements**     |                         |                     |                       |
| Yes                      | 41 (66.1)               | 0.91 (0.32–2.85)    | 0.86                  |
| No                       | 15 (68.2)               |                     |                       |
| **TDF exposure**         |                         |                     |                       |
| Yes                      | 20 (52.6)               | 3.24 (1.26–8.35)    | 0.01                  |
| No                       | 36 (78.3)               |                     |                       |
| **NNRTI exposure**       |                         |                     |                       |
| Yes                      | 23 (67.3)               | 1.08 (0.43–2.72)    | 0.87                  |
| No                       | 33 (66)                 |                     |                       |
| **Pls exposure**         |                         |                     |                       |
| Yes                      | 28 (59.6)               | 2.11 (0.82–5.46)    | 0.12                  |
| No                       | 28 (75.7)               |                     |                       |

Table 5: Analysis patients with vitamin D < 20 ng/mL at baseline.

|                          | Objective VitD > 20 ng/mL Yes: 156 (83.9) n (%) | p       | Objective: PTH < 65 pg/mL | p       |
|--------------------------|-----------------------------------------------|---------|---------------------------|---------|
| **VitD supplements**     |                                               |         |                           |         |
| Yes                      | 128 (95.5)                                   | 0.0001  | 90 (67.2)                 | 0.43    |
| No                       | 28 (53.8)                                    |         | 39 (73.1)                 |         |
| **TDF exposure**         |                                               |         |                           |         |
| Yes                      | 80 (89.9)                                    | 0.03    | 54 (60.7)                 | 0.02    |
| No                       | 76 (78.4)                                    |         | 74 (76.3)                 |         |
| **NNRTI exposure**       |                                               |         |                           |         |
| Yes                      | 75 (85.5)                                    | 0.58    | 61 (73.5)                 | 0.22    |
| No                       | 76 (82.5)                                    |         | 67 (65)                   |         |
| **Pls exposure**         |                                               |         |                           |         |
| Yes                      | 83 (84.7)                                    | 0.75    | 61 (62.2)                 | 0.04    |
| No                       | 73 (83)                                      |         | 67 (76.1)                 |         |

tolerated, safe, and effective, as more than 95% of the patients achieved vitamin D levels above 20 ng/mL, with the proposed schedule of administration.

In the current study, as in others, supplementation did not significantly affect calcium, phosphorus, and alkaline phosphatase during the period of observation. In addition, no differences were observed in the mean viral load, CD4 number, and CD4% between baseline and the end of the study. Moreover, in contrast to other studies, neither baseline concentration of vitamin D nor vitamin objectives were influenced by the cART use [20, 22, 40].

On the other hand, PTH elevation plays a direct role over bone disease among HIV-infected patients, as it acts on bone to release calcium and persistent PTH elevations are associated with bone loss across a range of clinical conditions [41–43]. Studies on evaluation of secondary hyperparathyroidism in HIV-infected patients are scarce; as a result there are few data on the impact of this condition on the health of individuals [44].

Because low vitamin D was associated with PTH increases, we hypothesized that vitamin D repletion may reduce the risk of PTH abnormalities. Many studies have shown that serum PTH is inversely related to serum 25(OH)D, and that with the increase in serum 25(OH)D there is a decrease in serum PTH that usually reaches a plateau. In the Endocrine Society guidelines [45], the statement is made that serum PTH reaches a plateau at a threshold of 30 ng/mL, but this is supported by only a few references, since in recent literature there is a large variability in the reported level of serum vitamin D at which PTH reached a plateau or was maximally suppressed [46]. In our study, as in others before, serum PTH was inversely correlated with serum 25(OH)D but no threshold as defined by suppression of serum PTH was found. Sai et al. showed similar results, but
they do found a threshold for bone markers that increased only below a vitamin D of approximately 18 ng/mL, so they conclude that vitamin D insufficiency should be defined as 25(OH)D < 20 ng/mL as it relates to bone. Although there is not much literature about PTH normalization, we report that 66.7% of the patients achieve PTH levels < 65 pg/mL after 2-year follow-up. We hypothesized that a longer follow-up may increase the number of patients that correct hyperparathyroidism because after supplementation the time it takes to normalize PTH is not set.

In different studies vitamin D has been associated with TDF-linked hyperparathyroidism emphasizing that both, TDF use and vitamin D status, influence in PTH values. Although the mechanism by which TDF produces hyperparathyroidism is unclear, a previous study suggests that the increased hydroxylation rates and tubular phosphate losses, which drive calcium preservation and possibly altered bone metabolism, are dependent on vitamin D status [47]. Moreover PTH elevations have been observed in patients under TDF treatment presented PTH values significantly higher which is consistent with other studies [51]. Although vitamin D treatment may decrease PTH in persons taking TDF in the absence of measurable vitamin D deficiency, in our study TDF or IP exposure was a risk factor for not achieving PTH objective. So it is suggested that because 1,25(OH)2D directly decreases PTH and vitamin D treatment increases 1,25(OH)2D and its direct effect may decrease PTH. But as hyperparathyroidism may be multifactorial in HIV-infected patients and TDF may have effects on other factors that directly increase PTH, vitamin D supplementation could be not enough to normalize PTH but to improve the levels as we have seen in the present study.

Limitations of the present study are mainly related to the observational design nature of the current analyses. In this respect, the results reported herein are only associations from which no conclusions regarding causality can be drawn. The 25(OH)D measurements were done along the whole year, independently of seasonality. On the other hand we did not examine sun exposure, nor intakes of dietary calcium, although dietary calcium deficiency is rare in our population due to Mediterranean diet, and serum calcium and phosphorus were normal during the complete follow-up. Calcium urinary excretion was not measured.

In conclusion we demonstrate that the proposed scheme for vitamin D supplementation in HIV-infected patients is safe and valid for correcting vitamin D abnormalities and to improve raised PTH levels, but not enough for normalizing them, especially in patients exposed to tenofovir or protease inhibitors.

Competing Interests
The authors declare no conflict of interests.

References
[1] M. R. Pinzone, M. di Rosa, M. Malaguarnera et al., “Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic,” European Review for Medical and Pharmacological Sciences, vol. 17, no. 9, pp. 1218–1232, 2013.
[2] J.-P. Viard, J.-C. Souberbielle, O. Kirk et al., “Vitamin D and clinical disease progression in HIV infection: Results from the EuroSIDA Study,” AIDS, vol. 25, no. 10, pp. 1305–1315, 2011.
[3] N. J. Mueller, C. A. Fux, B. Ledergerber et al., “High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naïve and successfully treated Swiss HIV patients,” AIDS, vol. 24, no. 8, pp. 1127–1134, 2010.
[4] U. C. Bang, S. A. Shakar, M. F. Hiltz et al., “Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: A Descriptive Cross-Sectional Study,” Scandinavian Journal of Infectious Diseases, vol. 42, no. 4, pp. 306–310, 2010.
[5] E. Lerma, M. E. Molas, M. M. Montero et al., “Prevalence and factors associated with vitamin D deficiency and hyperparathyroidism in HIV-infected patients treated in Barcelona,” ISRN AIDS, vol. 2012, Article ID 485307, 5 pages, 2012.
[6] J. H. Arnsten, R. Freeman, A. A. Howard, M. Floris-Moore, Y. Lo, and R. S. Klein, “Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection,” AIDS, vol. 21, no. 5, pp. 617–623, 2007.
[7] E. M. Stein, M. T. Yin, D. J. McMahon et al., “Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women,” Osteoporosis International, vol. 22, no. 2, pp. 477–487, 2011.
[8] E. T. Overton, K. Mondy, T. Bush et al., “Factors associated with low bone mineral density in a large cohort of HIV-infected US adults: baseline results from the SUN study,” in Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections, vol. 836 of abstract 836, Los Angeles, Calif, USA, February 2007.
[9] L. Gazzola, G. M. Bellisti, C. J. Tincati et al., “Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients,” Journal of Translational Medicine, vol. 11, article 51, 2013.
[10] V. Walker Harris and T. T. Brown, “Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies,” Journal of Infectious Diseases, vol. 205, no. 3, pp. S391–S398, 2012.
[11] W. G. Powderly, “Osteoporosis and bone health in HIV,” Current HIV/AIDS Reports, vol. 9, no. 3, pp. 218–222, 2012.
[12] D. Bikle, “Non classic actions of vitamin D,” The Journal of Clinical Endocrinology & Metabolism, vol. 94, pp. 24–34, 2009.
[13] T. Ansemant, S. Mahy, C. Piroth et al., “Severe hypovitaminosis D correlates with increased inflammatory markers in HIV infected patients,” BMC Infectious Diseases, vol. 13, no. 1, article 7, 2013.
[14] A. Conesa-Botella, C. Mathieu, R. Colebunders et al., “Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome?” AIDS Research and Therapy, vol. 6, article 4, 2009.
[15] M. F. Holick, N. C. Binkley, H. A. Bischoff-Ferrari et al., “Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 7, pp. 1911–1930, 2011.
[16] B. W. Hollis, “Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D,” The Journal of Nutrition, vol. 135, no. 2, pp. 317–322, 2005.
[17] C. Brot, P. Vestergaard, N. Kolthoff, J. Gram, A. P. Hermann, and O. H. Sorensen, “Vitamin D status and its adequacy in healthy Danish perimenopausal women: relationships to dietary intake,
sun exposure and serum parathyroid hormone," *British Journal of Nutrition*, vol. 86, no. 1, pp. S97–S103, 2001.

[18] C. M. Lenders, H. A. Feldman, E. Von Scheven et al., "Relation of body fat indexes to vitamin D status and deficiency among obese adolescents," *American Journal of Clinical Nutrition*, vol. 90, no. 3, pp. 459–467, 2009.

[19] M. Bluem, G. Dolnikowski, E. Seyoum et al., "Vitamin D3 in fat tissue," *Endocrine*, vol. 33, no. 1, pp. 90–94, 2008.

[20] M. Yin and E. Stein, "The effect of antiretrovirals on vitamin D," *Clinical Infectious Diseases*, vol. 52, no. 3, pp. 406–408, 2011.

[21] A. Pasquet, N. Viget, F. Ajana et al., "Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use?" *AIDS*, vol. 25, no. 6, pp. 873–874, 2011.

[22] A. Conesa-Botella, E. Florence, L. Lynen, R. Colebunders, J. Menten, and R. Moreno-Reyes, "Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen," *AIDS Research and Therapy*, vol. 7, article 40, 2010.

[23] D. Wohlf, M. Doroana, C. Orkin et al., "Change in vitamin D levels and risk of development of severe vitamin D deficiency lower among HIV-1-infected, treatment-naive adults receiving TMC278 compared with EFV: 48-week results from the phase III ECHO trial," in *Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections*, Boston, Mass, USA, 2011.

[24] T. T. Brown and G. A. McComsey, "Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D," *Antiviral Therapy*, vol. 15, no. 3, pp. 425–429, 2010.

[25] T. Welz, K. Childs, F. Ibrahim et al., "Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase," *AIDS*, vol. 24, no. 12, pp. 1923–1928, 2010.

[26] M. R. Pinzone, M. Di Rosa, B. M. Celesta et al., "LPS and HIV gp120 modulate monocyte/macrophage CYP27B1 and CYP24A1 expression leading to vitamin D consumption and hypovitaminosis D in HIV-infected individuals," *European Review for Medical and Pharmacological Sciences*, vol. 17, no. 14, pp. 1936–1950, 2013.

[27] European AIDS Clinical Society, *EACS Guidelines*, Version 71, 2014.

[28] M. F. Holick, "Vitamin D deficiency," *The New England Journal of Medicine*, vol. 357, no. 3, pp. 266–281, 2007.

[29] K. M. Sanders, A. L. Stuart, E. J. Williamson et al., "Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial," *The Journal of the American Medical Association*, vol. 303, no. 18, pp. 1815–1822, 2010.

[30] S. Bañón, M. Rosillo, A. Gómez, M. J. Pérez-Elias, S. Moreno, and J. L. Casado, "Effect of a monthly dose of calcidiol in improving vitamin D deficiency and secondary hyperparathyroidism in HIV-infected patients," *Endocrine*, vol. 49, no. 2, pp. 528–537, 2015.

[31] G. El-Hajj Fuleihan, R. Bouillon, B. Clarke et al., "Serum 25-Hydroxyvitamin D levels: variability, knowledge gaps, and the concept of a desirable range," *Journal of Bone and Mineral Research*, vol. 30, no. 7, pp. 1119–1133, 2015.

[32] J. Ghosn and J.-P. Viard, "Vitamin D and infectious diseases," *Presse Medicaile*, vol. 42, no. 10, pp. 1371–1376, 2013.

[33] P. Poowuttikul, R. Thomas, B. Hart, and E. Secord, "Vitamin D insufficiency/deficiency in HIV-infected inner city youth," *Journal of the International Association of Providers of AIDS Care*, vol. 13, no. 5, pp. 438–442, 2014.

[34] G. L. Colombo, S. Di Matteo, and F. Maggiolo, "Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen," *ClinicalEconomics and Outcomes Research*, vol. 5, no. 1, pp. 59–68, 2013.

[35] J. L. O’Connor, E. M. Gardner, S. B. Mannheimer et al., "Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial," *Journal of Infectious Diseases*, vol. 208, no. 1, pp. 40–49, 2013.

[36] R. P. Heaney, "The vitamin D requirement in health and disease," *Journal of Steroid Biochemistry and Molecular Biology*, vol. 97, no. 1–2, pp. 13–19, 2005.

[37] B. Dawson-Hughes, R. P. Heaney, M. F. Holick, P. Lips, P. J. Meunier, and R. Vieth, "Estimates of optimal vitamin D status," *Osteoporosis International*, vol. 16, no. 7, pp. 713–716, 2005.

[38] R. P. Heaney, M. S. Dowell, C. A. Hale, and A. Bendich, "Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D," *Journal of the American College of Nutrition*, vol. 22, no. 2, pp. 142–146, 2003.

[39] S. M. Arpadi, D. J. McMahon, E. J. Abrams et al., "Effect of supplementation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adolescents: A Randomized Clinical Trial," *American Journal of Clinical Nutrition*, vol. 95, no. 3, pp. 678–685, 2012.

[40] J. Fox, B. Peters, M. Prakash, J. Arribas, A. Hill, and C. Moecklinghoff, "Improvement in vitamin D deficiency following antiretroviral regime change: results from the MONET trial," *AIDS Research and Human Retroviruses*, vol. 27, no. 1, pp. 29–34, 2011.

[41] K. E. Childs, S. L. Fishman, C. Constable et al., "Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users," *AIDS Research and Human Retroviruses*, vol. 26, no. 8, pp. 855–859, 2010.

[42] E. N. Taylor, G. C. Curhan, and J. P. Forman, "Parathyroid hormone and the risk of incident hypertension," *Journal of Hypertension*, vol. 26, no. 7, pp. 1390–1394, 2008.

[43] O. Sahota, M. K. Mundey, P. San, I. M. Godber, N. Lawson, and D. J. Hosking, "The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis," *Bone*, vol. 35, no. 1, pp. 312–319, 2004.

[44] T. F. Marques, R. Vasconcelos, E. Diniz, D. Rêgo, L. Griz, and F. Bandeira, "Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat?" *Arquivos Brasileiros de Endocrinologia e Metabolologia*, vol. 55, no. 5, pp. 314–317, 2011.

[45] M. F. Holick, N. C. Binkley, H. A. Bischoff-Ferrari et al., "Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline," *The Journal of Clinical Endocrinology & Metabolism*, vol. 96, no. 7, pp. 1911–1930, 2011.

[46] A. J. Sai, R. W. Walters, X. Fang, and J. C. Gallagher, "Relationship between vitamin D, parathyroid hormone, and bone health," *The Journal of Clinical Endocrinology & Metabolism*, vol. 96, no. 3, pp. E436–E446, 2011.

[47] M. M. Rosenvinge, K. Gedela, A. J. Copas et al., "Tenofovir- linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency," *Journal of Acquired Immune Deficiency Syndromes*, vol. 54, no. 5, pp. 496–499, 2010.

[48] P. Daria, C. Laura, R. Elena et al., "Secondary hyperparathyroidism in HIV patients: is there any responsibility of highly active antiretroviral therapy?" *AIDS*, vol. 25, no. 11, pp. 1430–1433, 2011.
[49] C. K. Kwan, B. Eckhardt, J. Baghdadi, and J. A. Aberg, “Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York,” *AIDS Research and Human Retroviruses*, vol. 28, no. 9, pp. 1025–1032, 2012.

[50] A. Bech, P. Van Bentum, D. Telting, J. Gisolf, C. Richter, and H. De Boer, “Treatment of calcium and vitamin D deficiency in HIV-positive men on tenofovir-containing antiretroviral therapy,” *HIV Clinical Trials*, vol. 13, no. 6, pp. 350–356, 2012.

[51] K. Klassen, A. R. Martineau, R. J. Wilkinson, G. Cooke, A. P. Courtney, and M. Hickson, “The effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicity,” *PLoS ONE*, vol. 7, no. 9, article e44845, 2012.